Search or

𝛼SK

ENTITY

CStone Pharmaceuticals (2616 HK)

107

Analysis

Health Care • Hong Kong

CStone Pharmaceuticals operates as a biotechnology company. The Company develops immuno-oncology and molecularly targeted drugs to address unmet medical needs for cancer patients. CStone Pharmaceuticals serves customers worldwide.

more

Refresh

Exchange Announcement • 25 Nov 2025 12:05

Voluntary Announcement - European Commission Approved Sugmalimab For Stage Iii Non-Small Cell Lung Cancer

Exchange Announcement • 07 Nov 2025 08:00

Voluntary Announcement - Acaai 2025 | Cs2015 (Ox40l/Tslp Bispecific Antibody) Makes International Debut

Exchange Announcement • 04 Nov 2025 08:00

Voluntary Announcement - Cstone Announces Nmpa Approval Of Ind For The Phase Ii Clinical Trials Of Cs2009 (Pd-1/Vegf/Ctla-4 Tri-Specific Antibody) Combination Therapies, Further Exploring Its Therapeutic Potential

Exchange Announcement • 03 Nov 2025 08:05

List Of Directors And Their Role And Function

Exchange Announcement • 03 Nov 2025 08:04

(1) Appointment Of Independent Non-Executive Director; (2) Resignation Of Independent Non-Executive Director; And (3) Change In Composition Of Board Committees

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.7

x